Table 3 FDA recommended daily warfarin dosage (mg/d) based on VKORC1 and CYP2C9 genotypes
From: A clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement
VKORC1 c.-1639G/A | CYP2C9 *1/*1 | CYP2C9 *1/*2 | CYP2C9 *1/*3 | CYP2C9 *2/*2 | CYP2C9 *2/*3 | CYP2C9 *3/*3 |
|---|---|---|---|---|---|---|
GG | 5–7 | 5–7 | 3–4 | 3–4 | 3–4 | 0.5–2 |
GA | 5–7 | 3–4 | 3–4 | 3–4 | 0.5–2 | 0.5–2 |
AA | 3–4 | 3–4 | 0.5–2 | 0.5–2 | 0.5–2 | 0.5–2 |